| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 81.9% | 78.7% | ▼ -3.2% |
| Healthcare Services | 6.7% | 12.1% | ▲ +5.4% |
| Retailing | 5.1% | 5.6% | ▲ +0.5% |
| Insurance | 1.3% | 1.4% | ▲ +0.1% |
| Chemicals & Petrochemicals | 1.2% | 1.2% | ● +0.0% |
| Healthcare Equipment & Supplies | 0.7% | 0.8% | ▲ +0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.7% | 75.8% | ▼ -3.0% |
| Healthcare Services | 12.1% | 11.5% | ▼ -0.6% |
| Retailing | 5.6% | 5.4% | ▼ -0.3% |
| Chemicals & Petrochemicals | 1.2% | 1.3% | ▲ +0.1% |
| Insurance | 1.4% | 1.3% | ● -0.1% |
| Healthcare Equipment & Supplies | 0.8% | 0.8% | ● 0.0% |
Comparing May 2026 → Jun 2026
| # | Stock | Sector | Last Weight (May 2026) |
|---|---|---|---|
| 1 | Shilpa Medicare Ltd ₹46.03 Cr |
Pharmaceuticals & Biotechnology | 0.71% |
| 2 | Anthem Biosciences Limited ₹15.95 Cr |
Pharmaceuticals & Biotechnology | 0.25% |
| # | Stock | Sector | May 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| 1 | Alkem Laboratories Limited ₹375.79 Cr |
Pharmaceuticals & Biotechnology | 4.08% | 5.67% | +1.59% |
| 2 | Alembic Pharmaceuticals Limited ₹170.92 Cr |
Pharmaceuticals & Biotechnology | 1.76% | 2.58% | +0.82% |
| 3 | Dr. Reddy's Laboratories Limited ₹544.85 Cr |
Pharmaceuticals & Biotechnology | 7.70% | 8.22% | +0.52% |
| 4 | Abbott India Limited ₹163.73 Cr |
Pharmaceuticals & Biotechnology | 2.14% | 2.47% | +0.33% |
| 5 | Fine Organic Industries Limited ₹88.00 Cr |
Chemicals & Petrochemicals | 1.19% | 1.33% | +0.14% |
| 6 | Hikal Limited ₹88.55 Cr |
Pharmaceuticals & Biotechnology | 1.21% | 1.34% | +0.13% |
| 7 | Indoco Remedies Ltd ₹39.76 Cr |
Pharmaceuticals & Biotechnology | 0.47% | 0.60% | +0.13% |
| 8 | SANOFI CONSUMER HEALTHCARE ₹75.63 Cr |
Pharmaceuticals & Biotechnology | 1.02% | 1.14% | +0.12% |
| 9 | Sun Pharmaceutical Industries Limited ₹807.97 Cr |
Pharmaceuticals & Biotechnology | 12.09% | 12.20% | +0.11% |
| 10 | Blue Jet Healthcare Ltd ₹100.19 Cr |
Pharmaceuticals & Biotechnology | 1.40% | 1.51% | +0.11% |
| # | Stock | Sector | May 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| 1 | Biocon Limited ₹171.45 Cr |
Pharmaceuticals & Biotechnology | 4.71% | 2.59% | -2.12% |
| 2 | Cipla Limited ₹441.89 Cr |
Pharmaceuticals & Biotechnology | 7.45% | 6.67% | -0.78% |
| 3 | Lupin Limited ₹152.44 Cr |
Pharmaceuticals & Biotechnology | 3.06% | 2.30% | -0.76% |
| 4 | Aurobindo Pharma Limited ₹77.21 Cr |
Pharmaceuticals & Biotechnology | 1.92% | 1.17% | -0.75% |
| 5 | Divi's Laboratories Limited ₹368.88 Cr |
Pharmaceuticals & Biotechnology | 6.06% | 5.57% | -0.49% |
| 6 | JB Chemicals & Pharmaceuticals Limited ₹103.27 Cr |
Pharmaceuticals & Biotechnology | 1.94% | 1.56% | -0.38% |
| 7 | Max Healthcare Institute Limited ₹205.29 Cr |
Healthcare Services | 3.36% | 3.10% | -0.26% |
| 8 | Alivus Life Sciences ₹101.92 Cr |
Pharmaceuticals & Biotechnology | 1.77% | 1.54% | -0.23% |
| 9 | MedPlus Health Services Limited ₹242.21 Cr |
Retailing | 3.86% | 3.66% | -0.20% |
| 10 | EQ - WINDLAS BIOTEC LTD ₹51.39 Cr |
Pharmaceuticals & Biotechnology | 0.96% | 0.78% | -0.18% |
35 stocks — Jun 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹807.97 Cr |
Pharmaceuticals & Biotechnology |
12.20%
|
|
| 2 |
₹544.85 Cr |
Pharmaceuticals & Biotechnology |
8.22%
|
|
| 3 |
₹462.19 Cr |
Pharmaceuticals & Biotechnology |
6.98%
|
|
| 4 |
₹441.89 Cr |
Pharmaceuticals & Biotechnology |
6.67%
|
|
| 5 |
₹375.79 Cr |
Pharmaceuticals & Biotechnology |
5.67%
|
|
| 6 |
₹368.88 Cr |
Pharmaceuticals & Biotechnology |
5.57%
|
|
| 7 |
₹285.83 Cr |
Pharmaceuticals & Biotechnology |
4.31%
|
|
| 8 |
₹242.21 Cr |
Retailing |
3.66%
|
|
| 9 |
₹205.29 Cr |
Healthcare Services |
3.10%
|
|
| 10 |
₹191.64 Cr |
Healthcare Services |
2.89%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.